Login to Your Account


Aradigm shares fall 33%

FDA advisors considering Linhaliq, an experimental Aradigm Corp. drug for a rare but severe respiratory disease in patients with chronic lung infections, declined to support a new drug application for it, citing inconsistent efficacy data and concern over the endpoint of pivotal trials. more »


Our Habitat for All Things Science
Cholesterol precursor 'trains' innate immunity
Opinion


Partners in Focus